Ontology highlight
ABSTRACT: Background
Preclinical work and retrospective studies suggest that temozolomide chemotherapy in glioblastoma may be more effective when administered in the morning rather than the evening. Here we examine the effect of timing in a large cohort of patients in 2 contemporaneous randomized clinical trials.Methods
We assessed toxicity and survival data in patients with newly diagnosed glioblastoma enrolled in the CENTRIC EORTC 26071-22072 (n = 545, MGMT methylated) and CORE (n = 265, MGMT unmethylated) trials. We compared the outcome and toxicity of patients who took maintenance (adjuvant) temozolomide (TMZ) either in the morning (TMZ-m), afternoon (TMZ-a) or in the evening (TMZ-e).Results
In CENTRIC and CORE, n = 102/260 (39%) and 50/198 (25%) rece
SUBMITTER: Geurts M
PROVIDER: S-EPMC11913640 | biostudies-literature | 2025 Apr
REPOSITORIES: biostudies-literature